MEET DR. BRIAN MEHLING

Philanthropist and world-renowned orthopedic trauma surgeon

Dr. Brian Mehling, MD

Orthopedic Surgeon and Stem Cell Specialist

Dr. Brian Mehling is the founder and Chief Medical Officer of Blue Horizon International, LLC. Dr. Mehling is also a world-renowned orthopedic trauma surgeon whose mainstay of practice is in the greater New York City metropolitan area. Dr. Mehling completed his residency in Orthopedic Surgery at The St. Joseph’s Hospital, Patterson, New Jersey and performed his fellowship in sports medicine at Graduate Hospital, Philadelphia, Pennsylvania. He is an alumnus of The Ohio State University and also holds a Master’s of Science Degree in Biochemistry.

Blue Horizon International is a health care consulting company which combines cutting edge medical treatment and research with philanthropy. BHI provides resources and services to children and adults of all backgrounds, but especially those who are medically under-served. Dr. Mehling first conceived the Blue Horizon International Hospital concept while appraising differences in medical healthcare standards throughout Asia and the Middle East. Dr. Mehling recognized the truly significant need for universally high quality benchmarks in foreign nations and surmised that bringing the world’s best physicians to regions abroad would advance the standard of healthcare world-wide. In addition, American Nationals traveling in foreign lands would be able to receive the same quality of healthcare they have grown to expect at home. In association with Blue Horizon International, Blue Horizon’s Stem Cell Therapy Program provides an opportunity for the global community to participate in groundbreaking research while receiving stem cell therapy via state-of-the-art procedures provided in today’s western hospital safety conditions.

Uniquely positioned to take advantage of its clinical research, BHSC has safely and efficiently treated more than 600 patients with over 2,600 regenerative procedures documenting each procedure while tracking the progress of patients through their treatment cycle. Blue Horizon International Stem Cell Therapy Program is associated with The Stem Cell Centre, Hongqiao Brain Hospital and Wuhan University School of Basic Medical Science, Wuhan, China.

Dr Brian Mehling is Chairman of  Blue Horizon Charitable Foundation (BHCF). The Blue Horizon Charitable Foundation is a recognized 501 (c) (3) organization, dedicated to increasing the awareness of global inequalities in healthcare, as well as providing charitable medical care and education to adults and children in impoverished areas. The foundation raises capital in order to support medical centers and clinics by providing medicines vital to basic human survival, by performing advanced medical treatments otherwise not accessible to certain geographic regions, and to finance research and development in stem cell therapies and cellular regenerative medicine. BHCF also supports children around the world who have been orphaned as a result of disease and/or war. In order to raise awareness of these situations, BHCF produces documentary films that bring much needed attention to the plight of those with limited or no access to healthcare. The provision of these resources to less developed areas enables the medically underserved to benefit from high quality care and treatment.

Dr Mehling is also a documentary film producer and  President and CEO of Industrial Motion Pictures (IMP) , that produced the film Tiny Tears, debuting at the prestigious Cannes Film Festival.

Awards

Board Certification

American Board of Orthopedic Surgery Diplomate – July 2008

University of Texas Medical Branch Department of Internal Medicine Award

Heparin Induced Modification of Angiotensin-Converting Enzyme and Vascular Relaxation Effect Through Cell Remodeling in Cultured Endothelial Cells, 36th Annual National Student Research Forum, Galveston, Texas, April 6-8, 1995

Alpha Omega Alpha 1995 Student Research Fellowship

Fluorine-18-Fluorocaptopril as an In Vivo Probe of the Heparin Induced Changes in the Expression of Angiotensin-Converting-Enzyme in the Rat Model by Positron Emission Tomography with Histological, Immunolabeling, and Transmission Electron Microscopy Analysis

Wright State University Biomedical Research Grant

The Study of Trophoblastic and HIV-1 Cross Reactive Proteins, July 1993
Fluorine-18-Fluorocaptopril as an In Vivo Probe of the Heparin Induced Changes in the Expression of Angiotensin-Converting-Enzyme in the Rat Model by Positron Emission Tomography with Histological, Immunolabeling, and Transmission Electron Microscopy Analysis

WORK

Past and present

January 2007 - Present

Mehling Orthopedics, Hackensack, New Jersey

Sept 2003 – Present

Mehling Orthopedics, West Islip, New York - General orthopedics with emphasis on orthopedic trauma coverage

Jan 2002 – Dec 2003

Weatherby Locums: Forth Lauderdale, Florida - Orthopedic Emergency Room Coverage

Jan 2002 – July 2002

Frankford Hospitals Torresdale, Philadelphia, Pennsylvania

Aug 2002 – Dec 2002

Good Samaritan Hospital, West Islip, New York

Aug 2002 – Dec 2002

Premier Orthopedics and Sports Medicine, Fort Lee, New Jersey - General orthopedics with emphasis on orthopedic trauma coverage

Dec 2002 – Sept 2003

Good Samaritan Hospital, West Islip, New York - General orthopedics with emphasis on orthopedic trauma coverage

Teaching

Classroom Experience

The Ohio State University

Teaching Assistant for Biochemistry 521: Introduction to Biochemistry Laboratory, The Ohio State University, Fall 1991

The Wright State University

Tutor for First Year Medical Students in Gross Anatomy, Biochemistry, Physiology, Histology, and Microbiology, The Wright State University, September 1993 – May 1994

The Ohio State University

Teaching Assistant for Biology 101: Introduction to Biology, The Ohio State University, Winter 1992

Paper Publications

Notable published papers

Kidney International
Anil K. Mandel, Brian Mehling: Heparin-Induced Endothelial Cell Cytoskeletal Reorganization: A Potential Mechanism For Vascular Relaxation, Kidney International,Vol. 48 (1995) pp. 1508-16.
Rocky Mountain Bioengineering
Peter Barre, Brian Mehling: A Zinc Calcium Phosphorous Oxide Ceramic Organic Acid Vitamin E Composite for Repairing Bone Defects, Rocky Mountain Bioengineering Symposium, Copper Mountain, Colorado, April 5-11, 1995
Southern Biomedical Engineering
Peter Barre, Brian Mehling: A Zinc Calcium Phosphorous Oxide Ceramic and Mallic Acid-Calcium Hydroxide-Vitamine E Oil Composite for Repairing Bone Defects, 14th Southern Biomedical Engineering Conference, Shrieveport, Louisana, April 7-9, 1995
Microscopy and Microanalysis
Peter Barre, Brian Mehling, Suitability of a Zinc-Based Bioceramic for Repair of Bone Defects, Microscopy and Microanalysis, Kansas City, Missouri, 1995

 

Recent Publications

Education

June - Sept 1983

Harvard University; Cambridge, Massachusetts

June 1994

M.S. Biochemistry - Ohio State University; Columbus, Ohio

June 1989

B.A. Biochemistry – Ohio State University; Columbus, Ohio

1985, 1986
Honors

Dean’s List

June 1996

The Wright State University School of Medicine, Dayton, Ohio M.D.

1993, 1994
Honors

School of Medicine Scholarship

October 1995
Honors

Alpha Omega Alpha Honor Society

July 1996 – June 2001

St. Joseph’s Hospital, Paterson, New Jersey - Orthopaedic Surgery Residency

January 1997 – June 2011

Seton Hall University, South Orange, New Jersey - PhD. Chemistry

Aug 2001 – July 2002

Graduate Hospital, Philadelphia, Pennsylvania - Sports Medicine Fellowship

MEHLING ORTHOPEDICS

ABOUT THE PRACTICE

At Mehling Orthopedics, we treat patients like family. After an injury, you need the specialized care and follow-up from only the finest medical professionals available. Our physicians are board-certified and fellowship-trained with subspecialties in sports medicine, orthopedic trauma and sports-related injuries

 More about Mehling Orthopedics

CONTACT DETAILS

Collins Street West Victoria 8007 Australia

+1800 1234 56789

[email protected]

www.websitename.com

Shoot a message!

[contact-form-7 id=”69″ title=”Contact form 1″]